Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors
NCT05934084 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 552
Last updated 2026-01-12
Summary
This is a prospective randomized open-label, multicenter, 2-arm study to assess the role of healthy LifeStyle implemented Survivorship Care Plan (LS-SCP) in modifying the Quality of Life (QoL) in a population of long-term lymphoma survivors (in remission for a minimum 3 years since the last treatment and a maximum of 10 years).
Conditions
- Classical Hodgkin Lymphoma
- Diffuse Large B Cell Lymphoma (DLBCL)
- Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Interventions
- BEHAVIORAL
-
Lifestyles Implemented-Survivorship Care Plan (LS-SCP)
Patients in the experimental arm will follow the planned intervention (Survivorship Care Plan (SCP), nutritional plan, physical activity) for 6 months. A bi-monthly automatic call to assess the compliance at the experimental arm (LS-SCP, Lifestyles implemented-Survivorship Care Plan) will be performed.
Sponsors & Collaborators
-
Fondazione Italiana Linfomi - ETS
lead OTHER
Principal Investigators
-
Carla Minoia, MD · Bari, IRCCS Istituto Tumori Giovanni Paolo II - U.O.C Ematologia
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-02-26
- Primary Completion
- 2026-02-01
- Completion
- 2026-02-01
Countries
- Italy
Study Locations
More Related Trials
-
Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's Lymphoma
NCT06761274 ·Status: RECRUITING ·Phase: NA
-
Watch and Wait or Worry and Wait in Indolent Lymphoma
NCT07173790 ·Status: ENROLLING_BY_INVITATION
-
A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab
NCT01461928 ·Status: COMPLETED ·Phase: PHASE3
-
Transplantation After Complete Response In Patients With T-cell Lymphoma
NCT05444712 ·Status: RECRUITING ·Phase: NA
-
Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma
NCT01369784 ·Status: COMPLETED
-
A Complex Intervention for Chronically Fatigued Lymphoma Survivors
NCT05130099 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project
NCT06156774 ·Status: RECRUITING
-
Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma
NCT02313389 ·Status: UNKNOWN ·Phase: PHASE3
-
Indolent Non Follicular Lymphomas Prognostic Project
NCT02904577 ·Status: COMPLETED
-
Study of Prognostic Factors in Adult Lymphoblastic Lymphoma
NCT03571997 ·Status: UNKNOWN
-
Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma
NCT05058404 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Italian Multicenter Retrospective Observational Study on Transformed Lymphomas
NCT02927756 ·Status: UNKNOWN
-
An Italian Experience on Grade 3b Follicular Lymphoma
NCT02927717 ·Status: UNKNOWN
-
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
NCT01118234 ·Status: COMPLETED ·Phase: PHASE3
-
Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma
NCT00794261 ·Status: COMPLETED ·Phase: PHASE2
-
Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas
NCT02223208 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
PET Adapted Treatment of Patients With Limited Stage DLBCL and no Risk Factors
NCT05078840 ·Status: RECRUITING
-
A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma
NCT00930514 ·Status: COMPLETED ·Phase: PHASE1
-
Italian Study of Patients With Lymphoma
NCT06814925 ·Status: RECRUITING
-
Long-Term Follow-up Study
NCT05332054 ·Status: ENROLLING_BY_INVITATION
-
Treatment of Localized Low Grade Lymphomas
NCT00536458 ·Status: COMPLETED ·Phase: PHASE3
-
Follow-up of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia
NCT02896829 ·Status: COMPLETED
-
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
NCT06284122 ·Status: RECRUITING ·Phase: PHASE3
-
The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study
NCT07240194 ·Status: RECRUITING ·Phase: PHASE2
-
CNS Prophylaxis in Diffuse Large B-cell Lymphoma
NCT02777736 ·Status: UNKNOWN ·Phase: PHASE3